Adipose-Derived Biocellular Regenerative Therapy for Osteoarthritis

Launched by HEALEON MEDICAL INC · Jan 19, 2020

Keywords

ClinConnect Summary

**Clinical Trial Summary: Adipose-Derived Biocellular Regenerative Therapy for Osteoarthritis**

This clinical trial is exploring a new treatment for osteoarthritis (OA), a condition that causes pain and stiffness in the joints, affecting areas like the knees, hips, shoulders, and ankles. The goal is to use a patient’s own cells, specifically stem cells and growth factors, to help heal and reduce pain in the affected joints with a minimally invasive procedure. Unlike traditional treatments, such as surgeries that may not provide long-lasting relief, this study aims to track improvements over time for participants receiving this innovative therapy.

To be eligible for the trial, participants should be between the ages of 65 and 75 and have a diagnosis of osteoarthritis with documented inflammation or degeneration in their joints. It's important that they do not have any serious health conditions that could complicate the procedure, such as active infections or recent cancer treatments. Participants will receive personalized care and will be monitored closely to see how well this new treatment works for them. If you're interested in learning more or considering participation, please reach out to the study team for more information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Documented osteoarthritic inflammatory and/or degenerative changes in the joint or connective tissues of the knee, hip, shoulder, Achilles tendon, Sacroiliac Joint, wrist/hand, foot/ankle, or Plantar Fasciitis (PR);
• • No systemic disorders which, in opinion of principal investigator, would disqualify from safely being able to undergo the determined procedures;
• • Have the ability to understand and accept all items in Informed Consent Document;
• • Have adequate perivascular and extracellular matrix donor tissues available;
• • Mature enough to tolerate determined procedures and follow up instructions and complete post-treatment tracking responsibilities
• Exclusion Criteria:
• • Systemic or psychological impairment which would preclude patient tolerance and understanding nature and extent of procedures and follow up tracking;
• • Known active cancer, chemotherapy, or radiation therapy;
• • Pregnancy;
• • Active infections which would increase risk of patient to undergo treatment;
• • High dose steroid users, or recipients of corticosteroids with a six month period before treatment date;
• • Medication or Opiate addition, or in active treatment for drug rehabilitation;
• • History of documented severe traumatic brain injuries;
• • In the opinion of the principal investigator/provider, the patient's condition or medical issues which would not allow the individual to fully accomplish or complete the study requirements